sb 202190 has been researched along with Koch's Disease in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JE | 1 |
| Park, S | 1 |
| Cho, SN | 1 |
| Lee, H | 1 |
| Kim, YS | 1 |
1 other study available for sb 202190 and Koch's Disease
| Article | Year |
|---|---|
c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) are involved in Mycobacterium tuberculosis-induced expression of Leukotactin-1.
Topics: Anthracenes; Cell Line, Tumor; Chemokines, CC; Humans; Imidazoles; JNK Mitogen-Activated Protein Kin | 2012 |